Figure 4
MPM tumor xenografts feature high CDA expression and are more susceptible to schedule-dependent than concurrent therapy. (A) Representative image of CDA expression in a MESO-1 xenograft tumor. (B) In the periphery and center of each tumor, at least two regions with high and weak CDA intensities were selected for further H-score analysis. The tumor center was determined to be 1000 µm from the tumor edge. ***p < 0.001 according to an unpaired t test. (C) H-scores over time in untreated tumors (n = 2). (D) H-scores over time after treatment with one cycle of chemotherapy compared to those of the untreated control. The data are presented as the mean ± SEM (n = 4). **p < 0.01, comparison between groups by two-way ANOVA with Tukey’s multiple comparisons test. (E) Mouse body weight during the experiment shown in panel F. (F) Analysis of tumor growth over time in the MESO-1 xenograft tumors treated with the indicated regimens. The data were analyzed by two-way ANOVA with Tukey’s multiple comparisons test and are presented as the mean ± SEM (n = 4 or 5). **p < 0.01, ****p < 0.0001. (G) Tumor weight on day 100 after the start of the experiment. The data are presented as the mean ± SEM (n = 4 or 5). Not significant (ns), *p < 0.05, **p < 0.01, and ****p < 0.0001 according to unpaired t tests.
